Imfinzi Racks Up Another Phase III Failure, But AZ Undeterred

Combination Fails Again

AstraZeneca frustrated again, this time in bladder cancer where Imfinzi gained its first foothold. But its blockbuster success in lung cancer is giving AZ scope to continue with gambles in other tumor types.

AZCambridge_HQ
AstraZeneca's HQ in Cambridge, currently under construction • Source: AZ

AstraZeneca PLC has announced another failure for Imfinzi, this time as a monotherapy and in combination with CTL4 immunotherapy tremelimumab in unresectable, previously-untreated metastatic bladder cancer.

The failure of the Phase III DANUBE trial is the latest in a number of late-stage disappointments for Imfinzi (durvalumab)...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category